BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15519285)

  • 1. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease.
    Pearson TA
    Am J Cardiol; 2004 Nov; 94(9A):4F-8F. PubMed ID: 15519285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cholesterol: blood levels or total risk as a guide to preventive treatment?].
    Mathes P
    Z Kardiol; 2004; 93 Suppl 2():II16-20. PubMed ID: 15021991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimal serum cholesterol and efficacy of methods for lowering cholesterolemia].
    Emmerich J; Thomas D; Richard JL; Delahaye F; Bruckert E
    Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():59-65. PubMed ID: 1296546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ; Bilek S; Rosenbaum S
    Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
    Naslafkih A; Sestier F
    J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Statins in stroke prevention].
    Gedikli O; Baykan M
    Anadolu Kardiyol Derg; 2008 Jun; 8(3):217-22. PubMed ID: 18524729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The patient at risk: who should we be treating?
    Leitersdorf E
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do people with diabetes need statins?
    White JR
    Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary artery disease epidemic in Indians: a cause for alarm and call for action.
    Enas EA
    J Indian Med Assoc; 2000 Nov; 98(11):694-5, 697-702. PubMed ID: 11265799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.